Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents

BACKGROUND AND OBJECTIVE: HIV treatment options remain limited in children. Dolutegravir is a potent and well-tolerated, once-daily HIV-1 integrase inhibitor recommended for HIV-1 infection in both adults and children down to 4 weeks of age. To support pediatric dosing of dolutegravir in children, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandasana, Hardik, Thapar, Mita, Hayes, Siobhan, Baker, Mark, Gibb, Diana M., Turkova, Anna, Ford, Deborah, Ruel, Theodore, Wiznia, Andrew, Fairlie, Lee, Bwakura-Dangarembizi, Mutsa, Mujuru, Hilda, Alvero, Carmelita, Farhad, Mona, Hazra, Rohan, Townley, Ellen, Buchanan, Ann, Bollen, Pauline, Waalewijn, Hylke, Colbers, Angela, Burger, David, Acosta, Edward P., Singh, Rajendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520196/
https://www.ncbi.nlm.nih.gov/pubmed/37603217
http://dx.doi.org/10.1007/s40262-023-01289-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520196/
https://www.ncbi.nlm.nih.gov/pubmed/37603217
http://dx.doi.org/10.1007/s40262-023-01289-5

Ejemplares similares